1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment.
The compound 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine addresses the limitations of SSRIs by inhibiting serotonin reuptake and acting as a 5-HT3 antagonist with partial 5-HT1A agonism, enhancing cognitive function and providing rapid antidepressant effects.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- H LUNDBECK AS
- Filing Date
- 2026-04-15
- Publication Date
- 2026-07-07
AI Technical Summary
Existing selective serotonin reuptake inhibitors (SSRIs) have limitations, including a significant proportion of non-responders, slow onset of therapeutic effects, and do not effectively address cognitive impairment or depression, particularly in combination with other CNS-related disorders.
Development of a compound, 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine, which inhibits serotonin reuptake, acts as a 5-HT3 antagonist, and exhibits partial agonism at the 5-HT1A receptor, providing rapid therapeutic effects for depression and potential benefits for cognitive impairment.
The compound enhances cognitive function and provides rapid antidepressant effects by modulating serotonin receptors, offering improved treatment outcomes for depression and cognitive impairment, with reduced sexual side effects and enhanced bioavailability.
Smart Images
Figure 2026113713000033 
Figure 2026113713000034 
Figure 2026113713000035